Top of the morning to you. Another busy day is unfolding here on the Pharmalot campus, where we are mulling over our cluttered calendar and plotting our next moves. No doubt, you can relate. After all, this is only the middle of the week and there is so much to be done. This calls, as you may imagine, for a hot cup of stimulation. We are sticking with almond toffee for now, by the way. Feel free to join us. Meanwhile, here are some tidbits. The world is a busy place, yes? Hope you make your way today …

Pfizer (PFE) has agreed to pay up to $636 million for the rights to gene therapies under development at Vivet Therapeutics, The Wall Street Journal says. Gene therapies, which introduce new DNA into the body to address diseases caused by a single faulty gene, are attracting attention for their ability to cure intractable diseases. In the past month, both Roche (RHHBY) and Biogen (BIIB) have made bets on gene therapy. Vivet’s most advanced program is a gene therapy for Wilson disease, a rare, inherited liver disorder that causes the buildup of copper in the body.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy